Clinical trials
Metastatic Breast Cancer clinical trials
Below are recruiting metastatic breast cancer clinical trials, each written for real people, not researchers. We’re tracking 1,328 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04921137RecruitingPhase 4
Testing benefits and side effects of hormone therapy in older breast cancer patients
This study looks at the potential harms and benefits of hormone (endocrine) therapy in people age 70 and older with early-stage, hormone-receptor–positive breast cancer. It may help doctors choose which hormone treatment approach is safest and most helpful for older patients.
Edmonton, AlbertaAges 70 years+ - NCT04923542RecruitingPhase 1/Phase 2
Targeted drug plus focused brain radiation for breast cancer
This study tests whether abemaciclib (a targeted pill) given with focused radiation to brain tumors can control hormone receptor–positive, HER2-negative breast cancer in the brain. It’s designed to see if the combination helps shrink or slow the growth of brain metastases while keeping side effects manageable.
Tampa, FloridaAges 18 years+ - NCT07137416RecruitingPhase 1
Testing a new combination of cancer drugs for HER2-positive tumors and breast cancer
This trial tests the safety of combining two drugs, CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd), in people with HER2-positive solid tumors or certain types of breast cancer. If you have advanced cancer that hasn't responded to other treatments, this study may be an option.
Boston, MassachusettsAges 18 years+ - NCT06889610RecruitingPhase 2
Ablation plus drug therapy for advanced solid tumors
This trial tests combining a liver tumor ablation procedure with systemic drugs for people with advanced colorectal, breast, or melanoma cancer that has spread to the liver. The goal is to see if this approach can help when standard treatments have stopped working.
ShanghaiAges 18–80 - NCT06970912RecruitingPhase 2
ctDNA-Guided Reduced Chemo in HR+/HER2- Breast Cancer
This study is testing whether using a ctDNA blood test can help doctors decide if patients with hormone receptor-positive, HER2-negative breast cancer can safely receive less intensive chemotherapy after surgery. The goal is to reduce side effects while still preventing the cancer from coming back.
Beijing, Beijing MunicipalityAges 18–75 - NCT05142800Recruiting
Screening for Lymphedema in Breast Cancer Targeted Therapy
This study is looking at whether targeted therapy for breast cancer changes the risk of arm swelling (lymphedema). It is a screening trial that uses a machine to measure arm size and check for any swelling early on.
Boston, MassachusettsAges 18–80 - NCT07600164RecruitingPhase 4
Real-world study of pyrotinib treatment for advanced HER2-positive breast cancer
This study follows patients with advanced breast cancer that has a protein called HER2 to see how well pyrotinib (a targeted drug) works when used in routine clinical practice. You'd be tracked over time to understand how this treatment affects your cancer and quality of life.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07624617Recruiting
Fasting and Breast Cancer Treatment Study
This study looks at whether periods of fasting (eating for shorter time windows) might help improve how well a breast cancer medication called capivasertib works. You'll wear a glucose monitor, track your food, and follow fasting schedules while continuing your regular cancer treatment.
Minneapolis, MinnesotaAges 18 years+ - NCT04947189RecruitingPhase 1/Phase 2
Seviteronel plus chemo for advanced triple-negative breast cancer
This trial tests seviteronel together with standard chemotherapy to treat certain types of advanced breast cancer that has spread. It’s looking to see how well the combination works and how safe it is, especially for cancers that are androgen-receptor positive.
Darlinghurst, New South WalesAges 18 years+ - NCT04959474Recruiting
Pre-surgery radiation study with or without calorie restriction
This trial looks at whether a planned calorie-reduction diet before surgery can change how early breast cancer responds to a short course of radiation. It may help people understand if diet could improve outcomes alongside standard pre-surgery treatment.
Philadelphia, PennsylvaniaAges 40 years+ - NCT04965064RecruitingPhase 2
Neratinib plus capecitabine for HER2-negative breast cancer brain mets
This study tests whether neratinib plus capecitabine can slow or shrink breast cancer that has spread to the brain. It is for people whose cancer shows an “overactive HER2 signal” on a specific tumor test, even though their cancer is labeled HER2-negative.
Rochester, New YorkAges 18 years+ - NCT04965766RecruitingPhase 2
Study drug for HER2-negative, advanced breast cancer after prior treatment
This Phase 2 trial tests patritumab deruxtecan (U3-1402) in people with HER2-negative, hormone-receptor positive (HR+) breast cancer that cannot be removed by surgery or has spread. It’s for cancers that have progressed despite endocrine therapy plus a CDK4/6 inhibitor, aiming to shrink tumors and control the disease.
DijonAges 18 years+ - NCT04990921RecruitingPhase 2
Palliative radiation plus pembrolizumab for metastatic breast cancer
This trial studies whether adding a focused, comfort-focused form of radiation (SBRT) to pembrolizumab can help people with stage IV breast cancer that cannot be removed with surgery. You may be eligible if you can receive palliative SBRT and have measurable tumors, and if you meet prior-therapy and blood/health criteria.
Louisville, KentuckyAges 18 years+ - NCT05029999RecruitingPhase 1
Test drugs for HER2-negative advanced breast cancer
This Phase 1 trial tests a combination of immune-targeting drugs (a CD40 medicine and a substance that helps immune cells act) plus chemotherapy in people with HER2-negative advanced breast cancer that has progressed. It aims to find a safer dose and see whether the treatment can shrink tumors or slow the cancer.
Chicago, IllinoisAges 18–99 - NCT05035745RecruitingPhase 1/Phase 2
Selinexor plus talazoparib for advanced triple-negative breast cancer
This trial tests selinexor plus talazoparib in people with advanced, treatment-resistant solid tumors and, separately, advanced triple-negative breast cancer. It aims to see whether this combination can shrink tumors or slow their growth when standard options have not worked.
SingaporeAges 18–99 - NCT05058183Recruiting
Testing shorter chemotherapy for early HER2 or triple‑negative breast cancer
This study looks at whether some people with stage 1 HER2-positive or “triple-negative” breast cancer may safely need less (de-escalated) chemotherapy after surgery. The goal is to keep the cancer risk low while reducing treatment intensity, using special blood testing over time.
LondonAges 18 years+ - NCT05076760RecruitingPhase 1
Study of a cancer-killing virus with standard treatments
This Phase 1 trial tests MEM-288, an oncolytic (cancer-killing) virus, either alone or combined with standard cancer medicines, in people with advanced solid tumors. It’s designed to see how the treatment works and how safe it is in different cancer types and after specific prior therapies.
Tampa, FloridaAges 18 years+ - NCT05092373RecruitingPhase 1
Tumor treating device plus targeted or immune drugs for advanced cancers
This Phase 1 study tests whether a tumor treating fields device works better when added to standard cancer drugs. It may help people with advanced solid tumors in the chest or belly, especially when standard treatment didn’t work or can’t be tolerated.
Houston, TexasAges 18 years+ - NCT05095207RecruitingPhase 1/Phase 2
Abemaciclib and bicalutamide for HER2-negative metastatic breast cancer
This Phase 1/2 trial tests whether combining abemaciclib with bicalutamide can slow or shrink HER2-negative, androgen receptor–positive (AR-positive) metastatic breast cancer. It mainly looks at safety and side effects, and also whether the combination can help patients with this type of breast cancer.
New York, New YorkAges 18–90 - NCT05107674RecruitingPhase 1
Early drug study for advanced cancers that have limited options
This Phase 1 study tests NX-1607 in adults with advanced cancers that are hard to treat with standard care. It focuses on safety and early signs of how well the drug may work in specific cancer types.
Duarte, CaliforniaAges 18 years+ - NCT05181033RecruitingPhase 2
Lenvatinib plus letrozole versus fulvestrant for metastatic breast cancer
This Phase 2 study compares a combination medicine (lenvatinib plus letrozole) against fulvestrant to treat metastatic estrogen-receptor positive, HER2-negative breast cancer after the cancer has grown despite hormone therapy plus a CDK4/6 inhibitor. It may help by finding a more effective treatment option after your first lines have stopped working.
SingaporeAges 18–99 - NCT05187832RecruitingPhase 1
Study drug for ER-positive, HER2-negative breast cancer in postmenopausal women
This Phase 1 trial tests AND019, a new study drug, in postmenopausal women with advanced or metastatic ER-positive and HER2-negative breast cancer. It aims to see if the drug is safe and can control the cancer when other standard treatments have stopped working.
Nashville, TennesseeAges 18 years+ - NCT05205200RecruitingPhase 2
Immune therapy for HR-positive, HER2-negative metastatic breast cancer
This Phase 2 trial studies an immune-based treatment for women with HR-positive and HER2-negative breast cancer that has spread or returned and can’t be cured with local treatment alone. The goal is to see whether the therapy can shrink tumors and improve disease control with acceptable safety.
ShanghaiAges 18–75 - NCT05216432RecruitingPhase 1
RLY-2608 for PIK3CA-mutant advanced solid tumors and breast cancer
This early study (Phase 1) tests RLY-2608, a targeted cancer drug for tumors with a PIK3CA mutation. It studies the drug alone and combined with hormone therapy (and sometimes CDK4/6 or CDK4 medicines) to see safety, dose, and whether it can shrink tumors.
Tucson, ArizonaAges 18 years+
Hear when a new Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic breast cancer?
- Yes. Clin2 currently lists 1,328 recruiting metastatic breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- Breast Cancer (Triple Negative Breast Cancer (TNBC))
- Locally Advanced or Metastatic Breast Cancer
- Metastatic Triple-negative Breast Cancer
- HER2-positive Metastatic Breast Cancer
- Advanced/Metastatic Breast Cancer
- Non-metastatic Breast Cancer
- Advanced or Metastatic Breast Cancer
Beyond the search
We also like to point to nonprofits doing real good in this area. We aren’t affiliated with them — we just admire the work.
- Stand Up To CancerPeople facing cancer across many types, through the research that leads to better treatments.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.